More recently, a study comparing subjects with central obesity only with subjects suffering from the metabolic syndrome showed changes in ghrelin levels not to be associated with central obesity per se but with other components of the metabolic syndrome (524)
Notably, 21 percent of adults in February 2026 were not sure whether GLP-1s are risky or not
However, for some patients, these effects can be persistent and troublesome enough to warrant dose reduction or discontinuation
In a clinical trial participants lost an average of 15% of their body weight after 68 weeks
In clinical trials, tirzepatide led to substantial average weight loss, with higher doses generally producing greater reductions when combined with lifestyle changes
KO, n = 3 representative from 2 independent experiments, p = 0.0001) (c)